Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use

1. A solid nitrite salt of 1,1-dimethylbiguanide, or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof.

2. The nitrite salt of claim 1 , wherein the nitrite salt is 1,1-dimethylbiguanide mononitrite, or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof.

3. The nitrite salt of claim 1 , wherein the nitrite salt is 1,1-dimethylbiguanide dinitrite, or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof.

4. The nitrite salt of claim 1 , wherein the nitrite salt is in a crystalline form.

5. An isolated nitrite salt of 1,1-dimethylbiguanide, or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof.

6. A composition comprising the nitrite salt of claim 1 , or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof; and a metal nitrite.

7. The composition of claim 6 , comprising no less than about 90% of the nitrite salt of claim 1 , or the isotopic variant thereof; or the pharmaceutically hydrate or solvate thereof.

8. The composition of claim 6 , comprising no greater than about 10% of the metal nitrite.

9. A pharmaceutical composition comprising the nitrite salt of claim 1 , or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof; and a pharmaceutically acceptable excipient.

10. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for single dose administration.

11. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated as oral, parenteral, or intravenous dosage form.

12. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated as oral dosage form.

13. The pharmaceutical composition of claim 12 , wherein the oral dosage form is a tablet or capsule.

14. The pharmaceutical composition of claim 12 , wherein the oral dosage form is a tablet.

15. The pharmaceutical composition of claim 9 , wherein the pharmaceutically acceptable excipient is selected from candellila wax, cellulose acetate, corn starch, crospovidone or povidone, dibutyl sebacate, ethylcellulose, glyceryl behenate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, polysorbate, sodium carboxymethyl cellulose, sodium dioxide, sodium lauryl sulfate, synthetic black iron oxides, titanium dioxide, triacetin, and two or more combinations thereof.

16. The pharmaceutical composition of claim 9 , further comprising a second 1,1-dimethylbiguanide salt.

17. The pharmaceutical composition of claim 16 , wherein the second 1,1-dimethylbiguanide salt is a hydrochloric acid, hydrobromic acid, or sulfuric acid salt of 1,1-dimethylbiguanide.

18. The pharmaceutical composition of claim 16 , wherein the second 1,1-dimethylbiguanide salt is 1,1-dimethylbiguanide monohydrochloride.

19. The pharmaceutical composition of claim 9 , further comprising a second nitrite salt.

20. The pharmaceutical composition of claim 19 , wherein the second nitrite salt is sodium nitrite, potassium nitrite, or silver nitrite.

21. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition comprises the second nitrite salt in an amount ranging from about 1 to about 100 mg.

22. The pharmaceutical composition of claim 9 , further comprising an additional therapeutic agent.

23. The pharmaceutical composition of claim 22 , wherein the additional therapeutic agent is an additional antidiabetic agent.

24. The pharmaceutical composition of claim 23 , wherein the additional antidiabetic agent is an alpha-glucosidase inhibitor, an amylin analogue, a dipeptidyl peptidase 4 inhibitor, an incretin mimetic, a meglitinide, a non-sulfonylurea, a SGLT-2 inhibitor, a sulfonyl urea, or a thiazolidinedione, or a combination thereof.

25. The pharmaceutical composition of claim 24 , wherein the additional antidiabetic agent is acarbose, albiglutide, alogliptin, canagliflozin, ciglitazone, chlorpropamide, dapagliflozin, darglitazone, dulaglutide, empagliflozin, englitazone, exenatide, glimepiride, gliclazide, glipizide, glyburide, linagliptin, liraglutide, lixisenatide, lobeglitazone, miglitol, nateglinide, netoglitazone, pioglitazone, pramlintide, repaglinide, rosiglitazone, reviglitazone, saxagliptin, sitagliptin, tolbutamide, tolazamide, troglitazone, or a combination thereof.

26. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition comprises from about 1 to about 10,000 mg of the nitrite salt of 1,1-dimethylbiguanide, or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof and a pharmaceutically acceptable excipient.

27. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition comprises about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1,000, about 1,050, about 1,100, about 1,150, about 1,200, about 1,250, about 1,300, about 1,350, about 1,400, about 1,450, or about 1,500 mg of the nitrite salt of 1,1-dimethylbiguanide, or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof; and a pharmaceutically acceptable excipient.

28. The pharmaceutical composition of claim 26 , wherein the pharmaceutical composition comprises about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 mg of the nitrite salt of 1,1-dimethylbiguanide, or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof; and a pharmaceutically acceptable excipient.

29. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is a coated tablet.

30. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is an extended-release tablet.